- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06035159
The Feasibility, Usability and Satisfaction of an Online Tool for Perinatal Mental Health Problems (e-PMG)
The Feasibility, Usability and Satisfaction of an Online Tool for the Treatment of Anxiety and Depressive Symptoms in the Perinatal Period (From Pregnancy to 1 Year After Delivery)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
With the development and implementation of an online treatment tool, the existing online offer in Flanders (depression help, suicide) can be extended to pregnant women and women giving birth. This was necessary in the absence of a specific treatment offer for perinatal mental health problems.
In the framework of Project 2.0 of the Flemish Government, an online tool for the treatment of depressive and anxiety symptoms in the perinatal period has been developed by the Center for PMG UZ Gent (Mrs. Rita Van Damme, Prof. Dr. Gilbert Lemmens) in collaboration with the research group of Prof. Dr. Patrick Luyten (KUL). Online interventions have a wide reach, are easily accessible, have a destigmatizing effect and have a preventive function by reducing anxiety and depressive symptoms.
The online tool consists of 6 modules (parenting, relationships, self-care, emotions, cognitions and holding plan). It is recommended to do 1 module per week. The online tool will be launched in cooperation with OnlinePsyHulp, a GGZ group responsible for the website www.depressiehulp.be.
Through a mixed method study, the investigators aim to examine the feasibility, usability and satisfaction of the tool with a pre- and post measurement in preparation for a clinical trial. By means of an online application procedure, we will check whether participants applying to be enrolled in the study meet the inclusion criteria (pregnant woman or woman giving birth, partner of pregnant woman or woman giving birth, depressive or anxiety symptoms, 18 years or older, perinatal period (pregnancy to 1 year after birth), Dutch-speaking, living in Belgium). Participants meeting the inclusion criteria can enroll in the study after providing online informed consent, including email address.
At the start of the online tool, a number of demographic data (age, sex, marital status, education level, ethnicity, number of pregnancies, number of other (living) children, (expected) delivery date, current treatment modalities (medications, psychotherapeutic interventions, other), use of emotional support, psychiatric history) and questionnaires regarding depressive, anxiety and stress symptoms will be completed. These questionnaires, the Depression Anxiety Stress Scale (DASS 21-R) and the Edinburgh Postnatal Depression Scale (EPDS) will be repeated at follow-up (8 weeks after start). The question about other forms of treatment and use of emotional support will also be repeated at follow-up. The participant may receive up to 2 reminder emails (one per week) asking them to still complete these questionnaires after the online therapy. This should allow the researchers to calculate an effect through a pre-post measurement. In addition the investigators would like to conduct a qualitative thematic analysis on the feasibility, usability and satisfaction with the treatment program. This by means of the System Usability Scale (SUS) and 1 qualitative open-ended question on the usability of the tool (2 weeks after last login) and patient satisfaction after each lesson/module and 2 weeks after last login by means of qualitative questions (Likert scale and (open-ended) in-depth questions. When a participant does not log in for 2 weeks, an email is sent asking if they still intend to log in and if not to complete the qualitative questions. After this, a maximum of 1 reminder email may be sent.
Outcome measures are: 1) the reduction of depressive, anxiety and stress symptoms using DASS 21-R and EPDS (the latter to compare with other studies regarding depressive symptoms) after using the tool 2) the use of the online tool (via time logged in, number of logins and number of modules started, number of exercises completed), 3) the feasibility and understandability by the SUS and 1 qualitative open question regarding the usability of the tool 4) the determination of patient satisfaction through qualitative questions (Likert scale and (open-ended) in-depth questions.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rita Van Damme, phd-stduent
- Phone Number: +32 9 471 207350
- Email: rita.vandamme@uzgent.be
Study Contact Backup
- Name: Mathilde Descheemaeker, master
- Phone Number: +32 471 302511
- Email: mathilde.desceemaeker@uzgent.be
Study Locations
-
-
-
Gent, Belgium, 9000
- Recruiting
- University Hospital of Gent
-
Contact:
- Rita Van Damme
- Phone Number: +32471207350
- Email: rita.vandamme@uzgent.be
-
Contact:
- Mathilde Descheemaeker
- Phone Number: +32471302511
- Email: mathilde.descheemaeker@uzgent.be
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- pregnant or giving birth
- partner of pregnant/birthing woman
- depressive or anxiety symptoms,
- 18 years or older,
- perinatal period (pregnancy up to 1 year after birth),
- Dutch-speaking,
- living in Belgium
Exclusion Criteria:
- younger than 18 years of age,
- outside perinatal period,
- do not speak Dutch well enough,
- not resident in Belgium.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: online psychotherapy
All participants have access to the psychotherapeutic intervention, which consists of 6 modules.
Initially, we want to get information about the feasibility, comprehensibility and satisfaction of the participants with the tool.
Secondly, the effectiveness of the intervention will be assessed through a pre-post measurement.
|
6 modules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
use of the online tool, by means of time logged in
Time Frame: up to 10 weeks
|
time spent logged in (minutes)
|
up to 10 weeks
|
|
use of the online tool, by means of number of log-ins
Time Frame: up to 10 weeks
|
number of log-ins (number)
|
up to 10 weeks
|
|
use of the online tool, by means of number of lesson/modules started
Time Frame: up to 10 weeks
|
number of modules started (number)
|
up to 10 weeks
|
|
use of the online tool, by means of number of exercises completed
Time Frame: up to 10 weeks
|
number of exercises completed (number)
|
up to 10 weeks
|
|
usability of the online tool, by means of the System Usability Scale (SUS), when participant completes the program
Time Frame: through study completion, after each module (up to 10 wks)
|
the system usability scale, the SUS, total score
|
through study completion, after each module (up to 10 wks)
|
|
usability of the online tool, by means of the System Usability Scale (SUS) when participant no longer logs in and after invitation through email reminder
Time Frame: 2 weeks
|
the system usability scale, the SUS, total socre
|
2 weeks
|
|
usability of the online tool, by means of an open-ended qualitative question when participant completes the program.
Time Frame: through study completion, after each module (up to 10 wks)
|
a qualitative open question
|
through study completion, after each module (up to 10 wks)
|
|
usability of the online tool, by means of an open-ended qualitative question, when participant no longer logs in and after invitation through email reminder
Time Frame: 2 weeks
|
a qualitative open question
|
2 weeks
|
|
patient satisfaction, by means of qualitative questions when participant completes the program
Time Frame: through study completion, after each module (up to 10 wks)
|
qualitative questions (Likert scale)
|
through study completion, after each module (up to 10 wks)
|
|
patient satisfaction, by means of open-ended qualitative questions, when participant completes the program
Time Frame: through study completion, after each module (up to 10 wks)
|
qualitative questions (open-ended) in-depth questions
|
through study completion, after each module (up to 10 wks)
|
|
patient satisfaction, by means of qualitative questions when participant no longer logs in, and after invitation through email reminder
Time Frame: 2 weeks
|
qualitative questions (Likert scale)
|
2 weeks
|
|
patient satisfaction, by means of open-ended qualitative questions when participant no longer logs in and after invitation through email reminder
Time Frame: 2 weeks
|
qualitative questions (open-ended) in-depth questions.
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
reduction of depressive, anxiety and stress symptoms as pre-measurement
Time Frame: baseline
|
DASS 21-R, total score and scores of depressive scale (normal [0-9], mild [10-13], moderate [14-20], severe [21-27], extremely severe [28+]); anxiety scale (normal [0-7], mild [8-9], moderate [10-14], severe [15-19], extremely severe [20+]); stress scale (normal [0-14], mild [15-18], moderate [19-25], severe [26-33], extremely severe [34+]); Scores for depression, anxiety and stress are calculated by summing the scores for the relevant items.Scores on the DASS-21 will need to be multiplied by 2 to calculate the final score.
The DASS-21 is based on a dimensional rather than a categorical conception of psychological disorder.
|
baseline
|
|
reduction of depressive, anxiety and stress symptoms as post-measurement
Time Frame: study completion (up to 10 weeks)
|
DASS 21-R, total score and scores of depressive scale (normal [0-9], mild [10-13], moderate [14-20], severe [21-27], extremely severe [28+]); anxiety scale (normal [0-7], mild [8-9], moderate [10-14], severe [15-19], extremely severe [20+]); stress scale (normal [0-14], mild [15-18], moderate [19-25], severe [26-33], extremely severe [34+]); Scores for depression, anxiety and stress are calculated by summing the scores for the relevant items.Scores on the DASS-21 will need to be multiplied by 2 to calculate the final score.
The DASS-21 is based on a dimensional rather than a categorical conception of psychological disorder.
|
study completion (up to 10 weeks)
|
|
reduction of depressive and anxiety symptoms as pre-measurement
Time Frame: baseline
|
EPDS, total score (continuous and cut-off >= 13); EDS-3A(3 anxiety questions) (continuous and cut-off >= 5)
|
baseline
|
|
reduction of depressive, and anxiety symptoms as post-measurement
Time Frame: study completion (up to 10 weeks)
|
EPDS total score (continuous and cut-off >= 13); EDS-3A (3 anxiety questions)(continuous and cut-off >= 5)
|
study completion (up to 10 weeks)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Gilbert Lemmens, Prof, University Hospital of Gent - University of Gent
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ONZ-2022-0386
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
Massachusetts General HospitalRecruitingDepression | Depression - Major Depressive Disorder | Depression Chronic | Depression in Adults | Depression Disorders | Depression DisorderUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
ProgenaBiomeWithdrawnDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Sorlandet Hospital HFUniversity of Oslo; Karolinska Institutet; Australian Catholic University; Helse...RecruitingAnxiety | Anxiety Depression | Depression Anxiety Disorder | Depression - Major Depressive DisorderNorway
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Lipocine Inc.CompletedDepression, Postpartum | Postnatal Depression | Peripartum Depression | Depression, Post-Partum | Postpartum Depression (PPD) | Post-Natal DepressionUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryActive, not recruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Kolby Walker, DO; Brittany KimbleRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of CincinnatiNational Center for Complementary and Integrative Health (NCCIH)RecruitingMild DepressionUnited States
-
University of MinnesotaCompletedDepression SymptomsUnited States
Clinical Trials on online psychotherapy
-
Khushal Khan Khattak Univeristy, Karak, PakistanRecruitingMajor Depressive Disorder 1Pakistan
-
Institut Català d'OncologiaCompletedEmotional Disorder | Breastcancer | DistressSpain
-
University of Sao PauloUnknown
-
University Hospital TuebingenUniversity of Hohenheim; Universität TübingenCompletedObsessive-Compulsive DisorderGermany
-
Rakitzi, StavroulaRecruitingAnxiety | Recovery | Assertiveness | Depression - Major Depressive Disorder | Obsessive Compulsive Disorders | Anxiety Chronic | Functional OutcomeGreece
-
Central South UniversityFudan UniversityCompleted
-
University of California, Los AngelesFoundation for Women's HealthNot yet recruitingDepression | Perinatal DepressionUnited States
-
Universitätsklinikum Hamburg-EppendorfCompleted
-
Centre de Recherche de l'Institut Universitaire...Yale UniversityUnknownPsychotic Disorders | Anxiety DepressionCanada
-
St. Joseph's Healthcare HamiltonCorrectional Service of CanadaRecruitingSubstance Use Disorder (SUD)Canada